Moderna said Monday it plans to expand the size of its COVID-19 vaccine study in younger children to better detect rare side effects, such as a type of heart inflammation recently flagged by U.S. health authorities. The company said it is in talks with the Food and Drug Administration to enroll more study participants under age 12. It had intended to test the vaccine in about 7,000 children, with some ...
